{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jang KS"],"funding":["NHLBI NIH HHS"],"pagination":["7312-23"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4520396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["56(18)"],"pubmed_abstract":["4-[(18)F]Fluoro-m-hydroxyphenethylguanidine ([(18)F]4F-MHPG, [(18)F]1) is a new cardiac sympathetic nerve radiotracer with kinetic properties favorable for quantifying regional nerve density with PET and tracer kinetic analysis. An automated synthesis of [(18)F]1 was developed in which the intermediate 4-[(18)F]fluoro-m-tyramine ([(18)F]16) was prepared using a diaryliodonium salt precursor for nucleophilic aromatic [(18)F]fluorination. In PET imaging studies in rhesus macaque monkeys, [(18)F]1 demonstrated high quality cardiac images with low uptake in lungs and the liver. Compartmental modeling of [(18)F]1 kinetics provided net uptake rate constants Ki (mL/min/g wet), and Patlak graphical analysis of [(18)F]1 kinetics provided Patlak slopes Kp (mL/min/g). In pharmacological blocking stud"],"journal":["Journal of medicinal chemistry"],"pubmed_title":["4-[18F]Fluoro-m-hydroxyphenethylguanidine: a radiopharmaceutical for quantifying regional cardiac sympathetic nerve density with positron emission tomography."],"pmcid":["PMC4520396"],"funding_grant_id":["R01-HL079540","R01 HL079540"],"pubmed_authors":["Koeppe RA","Gu G","Jang KS","Sherman PS","Quesada CA","Jung YW","Raffel DM"],"additional_accession":[]},"is_claimable":false,"name":"4-[18F]Fluoro-m-hydroxyphenethylguanidine: a radiopharmaceutical for quantifying regional cardiac sympathetic nerve density with positron emission tomography.","description":"4-[(18)F]Fluoro-m-hydroxyphenethylguanidine ([(18)F]4F-MHPG, [(18)F]1) is a new cardiac sympathetic nerve radiotracer with kinetic properties favorable for quantifying regional nerve density with PET and tracer kinetic analysis. An automated synthesis of [(18)F]1 was developed in which the intermediate 4-[(18)F]fluoro-m-tyramine ([(18)F]16) was prepared using a diaryliodonium salt precursor for nucleophilic aromatic [(18)F]fluorination. In PET imaging studies in rhesus macaque monkeys, [(18)F]1 demonstrated high quality cardiac images with low uptake in lungs and the liver. Compartmental modeling of [(18)F]1 kinetics provided net uptake rate constants Ki (mL/min/g wet), and Patlak graphical analysis of [(18)F]1 kinetics provided Patlak slopes Kp (mL/min/g). In pharmacological blocking stud","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Sep","modification":"2025-04-19T07:19:59.486Z","creation":"2019-03-27T01:56:04Z"},"accession":"S-EPMC4520396","cross_references":{"pubmed":["23965035"],"doi":["10.1021/jm400770g"]}}